The use of post-genomic technologies for the diagnosis of cancer on the example of prostate cancer

Abstract

The last ten years have significantly changed the diagnostic and therapeutic technologies in research and practice. Human genome from a large international project turns into a basis of personalized medicine. The paper presents the positive experience of the new technology experimental thinking that led to the creation of complex scientific and technological platform that allows you to significantly improve the diagnostic characteristics (sensitivity, specificity) of the traditional PSA test. This paper presents the experimental results, which can improve the specificity and sensitivity of existing diagnostic methods.

Keywords

personalized medicine / prostate cancer / prostate specific antigen (PSA) / PSA test / laboratory medicine / predictive medicine / the medicine of the future / biomarker / personal norm

References

[1] Чиссов В.И., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздравсоцразвития России. 2012.

[2] Jemal A., Bray F., Center M. M. et al. Global cancer statistics. CA. Cancer J. Clin. 2011; 61(2): 69-90.

[3] Wang M.C., Valenzuela L.A., Murphy G.P, Chu T.M. Purification of a human prostate specific antigen. Invest. Urol. 1979; 17: 159-63.

[4] Catalona W.J., Partin A.W., Slawin K.M., Brawer M., Flanigan R., Patel A. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J. A. M. A. 1998; 279 (19): 1542-7.

[5] Catalona W.J., Smith D.S., Ratliff T.L., Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J. A. M. A. 1993; 270 (8): 948-54.

[6] Nam R.K., Zhang W.W., Trachtenberg J., Seth A., Klotz L.H., Stanimirovic A. et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin. Cancer Res. 2009; 15(5): 1787-93.

[7] Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C. , Jentzmik F. et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer. 2010; 126(5): 1166-76.

[8] Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M, Downs J. The PSA era in the United States is over for prostate cancer: what happened in the past 20 years? J. Urol. 2004; 172(4): 1297-301.

[9] Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C. M., Lucia M.S, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 2006; 98(8): 529-34.

[10] Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. Screening and prostate cancer mortality in a randomized European study. N. Engl. J. Med. 2009; 360(13): 1320-8.

[11] Stephenson A.J., Scardino P.T., Eastham J. A., Bianco F.J., Dotan Z.A., Fearn P. A. et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Nat. Cancer Inst. 2006; 98(10): 715-7.

[12] Zheng S.L., Sun J., Wiklund F., Smith S., Stattin P., Li G. et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 2008; 358, 910-19.

[13] Cheville J.C., Karnes R.J., Therneau T.M., Kosari F., Munz J.- M., Tillmans L. et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J. Clin. Oncology. 2008; 26(24): 3930-6.

[14] Koh C.M., Bieberich C.J., Dang C.V., Nelson W.G., Yegnasubramanian S., De Marzo A.M. MYC and prostate cancer. Genes and Cancer. 2010; 1(6): 617-28.

[15] Andriole G.L., Crawford E.D., Buys S.S., Grubb R.L. III et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009; 360: 1310-9.

[16] Schroder F.H., Hugosson J., Roobol M.J. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009; 360: 1320-8.

RIGHTS & PERMISSIONS

Eco-Vector